35%
Referral response in one patient-referral pilot
Research
46 of 133 cancer patients received a response when Ancora.ai used contact information listed on ClinicalTrials.gov in the Tufts Center for the Study of Drug Development (Tufts CSDD)/Ancora.ai pilot.
Why it matters: Patient interest still needs a clear response and next step.
Evidence detail
Cancer-only, 17 countries, pilot data, and not a universal referral-response rate.

